尽管对神经退化性疾病的临床试验很有希望,但阿蒂拉·法尔马(Athira Pharma)击败了收入估计,但库存却下降了。 Athira Pharma beat earnings estimates but saw stock fall, despite promising clinical trials for neurodegenerative diseases.

Athira Pharma是一家开发神经退化性疾病的治疗的公司,报告季度收入为每股0.39美元,殴打分析师的估计数额为0.45美元。 Athira Pharma, a company developing treatments for neurodegenerative diseases, reported quarterly earnings of ($0.39) per share, beating analysts' estimates of ($0.45). 然而,其库存在新闻上下降了0.02美元至0.42美元。 However, its stock fell $0.02 to $0.42 on the news. 公司的主要产品Fosgonimeton 正在接受老年痴呆症、帕金森痴呆症和痴呆病的临床试验。 The company's lead product, Fosgonimeton, is in clinical trials for Alzheimer's, Parkinson's dementia, and Dementia with Lewy bodies. 尽管股票下跌,其平均价格表明有潜在增长。 Despite the stock drop, its average prices suggest potential growth.